跳至主要内容
临床试验/DRKS00031316
DRKS00031316尚未招募3 期

PET-guided Radiosurgery of Oligometastatic Cancer - PETOC

Städtisches Klinikum Dessau0 个研究点目标入组 198 人开始时间: 2023年3月2日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
198

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • ICD-10: C00-25, C30-34(NSCLC only), C37, C39, C44-45, C48, C50 (hormone-resistant only), C51-58, C60-61 (castration-resistant only), C63-69, C73-74, and C80
  • oligometastatic disease with =5 extracranial lesions and =3 intrecebral lesions wihtout presious treatment, after relapse after complete remission or partial remission
  • patient qualifies for cytotoxic systemic therapy
  • normal blood counts (Hb>8g/dl, ANC>1500/mm³, thrombocytes >100 000/mm³)
  • normal liver function tests (ASAT/ALAT/AP=2.5*ULN), if liver metastatic and to be treated: <5*ULN
  • Bilirubin <1,5*ULN
  • Creatinin clearance (Cockroft-Gault) > 50 ml/min
  • ability to understand research protocol and willing to comply with reassessments and follow-ups
  • consent to have the patient’s case re-discussed in interdisciplinary tumor boards.
  • negative pregnancy test for female patients aged <50 yrs.
  • if sexually active, ability to use pregnancy prevention methods until 12 months after ending chemotherapy.
  • male patients restrain from fostering a child until 12 months after last chemotherapy

排除标准

  • Extragonadal germ cell tumor
  • Tumor or carcinoma with neuroendocrine features
  • Peritoneal carcinomatosis
  • Hormone-sensitive breast cancer
  • Hormone-sensitive prostate cancer
  • Chorioncarcinoma
  • Hematooncological neoplasia
  • Chemotherapy within the last three months
  • Age = 18 yrs.
  • previous radiotherapy to at least one of the areas currently presenting with oligometastatic disease, exceptions are brain metastasis, and metastasis with compression of the spinal cord
  • pregnancy or lactation
  • patients not compliant with birth control measurements
  • previous or ongoing abuse of medical substances, drugs, or alcohol
  • non-compliance in respect of protocol requirements and follow-ups
  • uncontrolled physical or mental disabilities
  • -including instable angina
  • -cardiac ischemia within the last 3 months
  • -active/treated neurological/psychiatric diagnosis incl. dementia/seizures
  • - active, not controlled infectious disease or bacteremia
  • patients with a history of previous malignant disease, except successfully treated basal cell cancer of the skin or carcinoma-in-situ of the uterine cervix.

研究者

发起方
Städtisches Klinikum Dessau

相似试验

已完成
不适用
Stereotactic Radiosurgery for limited brain metastasis using different techiniques&#44; Helical Tomotherapy&#44; Volumetric Modulated Arc Therapy and Cone&#45;based Linac radiosurgeryPatients with known primary cancer who develop limited brain metastasis (less than 4 lesions) and received stereotactic radiosurgery will be enrolled to this studystereotactic radiosurgery&#44Helical Tomotherapy (HT)&#44Volumetric Arc Therapy (VMAT)&#44Cone&#45based Linac radiosurgery (cone&#45based)
TCTR20200803006Faculty of Medicine&#44; Chiang Mai University21
招募中
2 期
Stereotactic Radiotherapy for Metastasis to the Lunglung malignancy100386661002910710038737lung cancer
NL-OMON35375Erasmus MC, Universitair Medisch Centrum Rotterdam30
已完成
不适用
Positron emission tomography (PET) guided therapy of diffuse large B-cell non-Hodgkin&#39;s lymphoma (DLBCL) with or without high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT)Diffuse large B-cell lymphoma
JPRN-UMIN000004420Japan Study Group for Cell Therapy and Transplantation68
进行中(未招募)
不适用
Radio-controlled Surgery RGS in the cancer of the rectum clinical study of feasibility to improve the treatment and prognosis - NDcarcinoma of the rectumMedDRA version: 8.1Level: PTClassification code 10038038Term: Rectal cancer
EUCTR2006-001499-18-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI30
进行中(未招募)
1 期
Radiotherapy of multiple brain metastases using AGuIX® gadolinium-chelated polysiloxane based nanoparticles: a prospective randomized phase II clinical trial.
EUCTR2018-001879-20-FRGrenoble Alps University Hospital100